Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah
Executive Summary
Gilead's newly acquired CAR-T therapy Yescarta, developed by Kite Pharma, won FDA approval for certain B cell lymphomas on Oct. 18 and the company set its price $102,000 below Novartis's competing therapy Kymriah, which was approved in a small pediatric leukemia indication.
You may also be interested in...
Kite’s Yescarta Is First CAR-T To Move Into Second-Line Lymphoma
Kite beats BMS’s Breyanzi to the first CAR-T approval in second-line large B-cell lymphoma. The added indication could nearly double the number of potential US patients for Yescarta.
Yescarta, Breyanzi Offer Practice-Changing Options For Second-Line LBCL
Data at ASH show CAR-T therapies may replace standard of care in an earlier line of large B-cell lymphoma with similar response rates and event-free survival for Kite’s established Yescarta and Bristol’s newer Breyanzi.
Gilead/Kite’s Tecartus Moves Into Leukemia With Second US Indication
New indication for second-line-plus acute lymphoblastic leukemia means Tecartus will compete with Novartis’s Kymriah, although the Gilead/Kite product is approved for older patient base.